US data arrives

New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 2021 https://www.cdc.gov/mmwr/volumes/70/wr/mm7034e1.htm?s_cid=mm7034e1_w New study from New York First to assess vaccine protection against coronavirus infection in delta times Data for New York May 3 to July 25 N = 10.5 million Modest drop in vaccine effectiveness against lab confirmed infection May 3, 91.7% July 25, 79.8% But Age adjusted effectiveness against hospitalizations May 3, 91.9% to 95.3% July 25, 91.9% to 95.3% Factors Delta up from 2% to 80% Widespread relaxations Implications Currently authorized vaccines have high effectiveness against COVID-19 hospitalization, but effectiveness against new cases appears to have declined in recent months these findings support the implementation of a layered approach centered on vaccination, as well as other prevention strategies Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare Safety Network, March 1–August 1, 2021 N = 85,593 weekly reports mRNA vaccines https://www.cdc.gov/mmwr/volumes/70/wr/mm7034e3.htm?s_cid=mm7034e3_w Effectiveness against infection declined in nursing homes as delta increased March, 75% June, 53% Vaccination for visitors and staff is crucial, additional doses of COVID-19 vaccine might be considered for nursing home and long-term care facility residents Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021 N = 1,129 diagnosed patients https://www.cdc.gov/mmwr/volumes/70/wr/mm7034e2.htm?s_cid=mm7034e2_w Analysis of patients at 21 hospitals After 2 doses of mRNA vaccine Across 18 states Substantial protection against hospitalizations No decline in protection against hospitalization over 24 weeks Effectiveness was steady at 86% percent Immunocompetent adults, 90% protection Remained constant during delta surge At 2 to 12 weeks after second dose, 86% At 13 to 24 weeks after second dose, 84% CDC director Rochelle Walensky https://www.washingtonpost.com/health/2021/08/18/covid-vaccine-effectiveness/ Examining numerous cohorts through the end of July and early August, three points are now very clear First, vaccine-induced protection against SARS-CoV-2 infection begins to decrease over time. Second, vaccine effectiveness against severe disease, hospitalization and death remains relatively high. And third, vaccine effectiveness is generally decreased against the delta variant Learn more about your ad choices. Visit megaphone.fm/adchoices